Nektar v. Lilly: Lilly Defeats CRE Claim, But Jury Finds It Owes $90M For Breaching The Implied Covenant Of Good Faith And Fair Dealing
A federal jury ruled that Eli Lilly & Co. breached the implied covenant of good faith and fair dealing with Nektar Therapeutics, awarding Nektar $90 million in damages. The jury rejected Nektar's claim that Lilly breached the license agreement's commercially reasonable efforts (CRE) obligation. Lilly plans to appeal, arguing no liability should have been imposed. The case highlights risks in biopharma licensing agreements.
How this was made
The 30-second read
Why it matters
The verdict introduces new legal exposure for Lilly and a cash windfall for Nektar, affecting their respective valuations and prompting sector‑wide attention to licensing risk.
Market read
The ruling creates immediate trading considerations for LLY (potential downside) and NKTR (potential upside) and underscores legal risk in biotech licensing.
What to watch
Potential insurance recoveries or indemnity clauses could mitigate the financial impact on Lilly.
Background
The article details the jury's findings on the implied covenant breach and the $90 M damages award, providing context on the license agreement and prior acquisition of Dermira.
Ticker impact
A federal jury awarded Nektar $90 million after finding Eli Lilly breached the implied covenant of good faith and fair dealing in their Rezpeg license agreement.
likely downward pressure as the market prices in the $90 M damages award and possible appeal costs
The $90 M judgment is a fresh, material legal exposure for Lilly; such news typically triggers short‑term sell‑side reaction.
Nektar Therapeutics secured a $90 million jury award after a lawsuit against Eli Lilly over the Rezpeg license deal.
potential upside as investors price in the cash infusion and precedent for future licensing disputes
A $90 M cash award is a significant, unexpected inflow for a biotech of Nektar's size, likely to be viewed favorably.
Market effects
The case highlights heightened legal risk in biopharma licensing agreements, prompting scrutiny of similar contracts across the sector.
Limited to U.S. biotech and pharma equities; no broader regional effect.
Modest; primarily relevant to investors in U.S. biotech stocks and legal‑risk assessments.
Counterpoint
If Lilly successfully appeals, the $90 M award may be reversed, limiting downside risk.
Key entities
- CompanyEli Lilly & Co.
Pharmaceutical company found liable for implied covenant breach.
- CompanyNektar Therapeutics
Biotech firm awarded $90 M after jury verdict.
